danafarberbostonchildrens.org
Jun 23, 2025, 11:22
Riten Kumar Shared New ISTH Data: 3-Month Apixaban Course Shows Better Safety Profile Than Rivaroxaban in Acute VTE
Riten Kumar, Associate Professor of Pediatrics at Harvard, posted on X:
“Late breaking abstract at isth – 3 months of apixaban is safer than rivaroxaban for management of acute VTE!!!”
Be updated with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology